Show simple item record

dc.contributor.authorCharkhpour, M
dc.contributor.authorJafari, RM
dc.contributor.authorGhavimi, H
dc.contributor.authorGhanbarzadeh, S
dc.contributor.authorParvizpur, A
dc.date.accessioned2018-08-26T08:52:03Z
dc.date.available2018-08-26T08:52:03Z
dc.date.issued2014
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53611
dc.description.abstractBackground: Long term exposure to morphine can induce dependence. The exact mechanisms of dependence are not yet fully understood. Many studies have been conducted to find new drugs that can prevent dependence. This study examined the effects of the chronic administration of duloxetine on the morphine withdrawal syndrome in rats. Methods: To this end, male Wistar rats (170-220 g) were randomly divided into 5 groups including one saline treated group (non-dependent group) and 4 morphine dependent groups. The experimental groups received additive doses of morphine for 9 days in order to induce dependence according to the following protocol: day 1: 5 mg/kg/12 h, days 2 and 3: 10 mg/kg/12 h, days 4, 5: 15 mg/kg/12 h, days 6 and 7: 20 mg/kg/12 h and days 8 and 9: 25 mg/kg/12 h. On the ninth day, the morning dose of morphine was only injected. It is worth noting that 30 min before the morning dose of morphine, duloxetine (10, 20, and 40 mg/kg) was injected intraperitoneally. In addition, 2 h after the last injection of morphine, the morphine withdrawal was precipitated by naloxone. The withdrawal signs were recorded for 30 min; these signs included jumping, rearing, genital grooming, abdominal writhing, wet dog shaking, and teeth grinding. Results: The results of the study revealed that the chronic administration of duloxetine decreased all the withdrawal signs. Besides, it attenuated the total withdrawal scores significantly. Conclusion: Results indicate that the regulatory effects on serotonergic and noradrenergic parameters might be associated with the amelioration of the withdrawal symptoms. é Georg Thieme Verlag KG Stuttgart آ· New York.
dc.language.isoEnglish
dc.relation.ispartofDrug Research
dc.subjectduloxetine
dc.subjectmorphine
dc.subjectnaloxone
dc.subjectsodium chloride
dc.subjectantidepressant agent
dc.subjectdopamine uptake inhibitor
dc.subjectduloxetine
dc.subjectnaloxone
dc.subjectnarcotic antagonist
dc.subjectserotonin uptake inhibitor
dc.subjectthiophene derivative
dc.subjectanimal behavior
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectarticle
dc.subjectbruxism
dc.subjectchronic drug administration
dc.subjectcontrolled study
dc.subjectgrooming
dc.subjectjumping
dc.subjectlight dark cycle
dc.subjectmale
dc.subjectmorphine addiction
dc.subjectmorphine withdrawal syndrome
dc.subjectnonhuman
dc.subjectrat
dc.subjectrearing
dc.subjectwet dog shakes
dc.subjectwithdrawal syndrome
dc.subjectwrithing test
dc.subjectanimal
dc.subjectdrug effects
dc.subjectintraperitoneal drug administration
dc.subjectMorphine Dependence
dc.subjectpsychology
dc.subjectSubstance Withdrawal Syndrome
dc.subjectWistar rat
dc.subjectAnimals
dc.subjectAntidepressive Agents
dc.subjectBehavior, Animal
dc.subjectDopamine Uptake Inhibitors
dc.subjectInjections, Intraperitoneal
dc.subjectMale
dc.subjectMorphine Dependence
dc.subjectNaloxone
dc.subjectNarcotic Antagonists
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectSerotonin Uptake Inhibitors
dc.subjectSubstance Withdrawal Syndrome
dc.subjectThiophenes
dc.titleDuloxetine attenuated morphine withdrawal syndrome in the rat
dc.typeArticle
dc.citation.volume64
dc.citation.issue8
dc.citation.spage393
dc.citation.epage398
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1055/s-0033-1358728


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record